Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Equity Average: 2009-2024

Historic Equity Average for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$323.8 million.

  • Ironwood Pharmaceuticals' Equity Average rose 9.59% to -$286.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.2 million, marking a year-over-year increase of 9.59%. This contributed to the annual value of -$323.8 million for FY2024, which is 311.59% down from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Equity Average is -$323.8 million, which was down 311.59% from $153.0 million recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Equity Average peaked at $629.1 million during FY2022, and registered a low of -$323.8 million during FY2024.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Equity Average value was $153.0 million (recorded in 2023), while the average stood at $152.8 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Equity Average soared by 2,284.02% in 2021 and then slumped by 311.59% in 2024.
  • Ironwood Pharmaceuticals' Equity Average (Yearly) stood at -$15.3 million in 2020, then soared by 2,284.02% to $334.3 million in 2021, then skyrocketed by 88.21% to $629.1 million in 2022, then plummeted by 75.67% to $153.0 million in 2023, then crashed by 311.59% to -$323.8 million in 2024.